Cannabinoids, the Heart of the Matter.

Authors: Naghum Alfulaij, Franziska Meiners, Justin Michalek, Andrea L. Small‐Howard, et al
Journal of the American Heart Association, 13 July 2018

Cardiovascular disease (CVD) is a global epidemic representing the leading cause of death in some Western countries. According to the American Heart Association, a total of 92.1 million US citizens currently have ≥1 forms of CVD, with numbers expected to grow reaching up to 4…

Marijuana intoxication in a cat.

Authors: Agnieszka Janeczek, Marcin Zawadzki, Pawel Szpot, Artur Niedzwiedz
Acta Veterinaria Scandinavica, 11 July 2018

BACKGROUND: Cannabis from hemp (Cannabis sativa and C. indica) is one of the most common illegal drugs used by drug abusers. Indian cannabis contains around 70 alkaloids, and delta-9-tetrahydrocannabinol (delta-9-THC) is the most psychoactive substance. Animal intoxications oc…

Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction.

Authors: Cecelia P. Johnson-Sasso, Christine Tompkins, David P. Kao, Lori A. Walker
PLoS One, 11 July 2018

Marijuana use is increasing worldwide, and it is ever more likely that patients presenting with acute myocardial infarctions (AMI) will be marijuana users. However, little is known about the impact of marijuana use on short-term outcomes following AMI. Accordingly, we compared…

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, et al
Journal of Neurology, Neurosurgery & Psychiatry, July 2018

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerab…

Marijuana Use in Adults Living with Sickle Cell Disease.

Authors: John D. Roberts, Jonathan Spodick, Joanna Cole, Janis Bozzo, Susanna Curtis, Ariadna Forray
Cannabis and Cannabinoid Research, July 2018

Introduction: Legal access to marijuana, most frequently as “medical marijuana,” is becoming more common in the United States, but most states do not specify sickle cell disease as a qualifying condition. We were aware that some of our patients living with sickle cell disease…

Self-initiated use of topical cannabidiol oil for epidermolysis bullosa.

Authors: Malcolm P. Chelliah, Zachary Zinn, Phoung Khuu, Joyce M. C. Teng
Pediatric Dermatology, July 2018

Epidermolysis bullosa is a rare blistering skin disorder that is challenging to manage because skin fragility and repeated wound healing cause itching, pain, limited mobility, and recurrent infections. Cannabidiol, an active cannabinoid found in cannabis, is postulated to have…

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.

Authors: Lisa R. Bartner, Stephanie McGrath, Sangeeta Rao, Linda K. Hyatt, Luke A. Wittenburg
Canadian Journal of Veterinary Research, July 2018

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dos…

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Authors: Lauri-Jo Gamble1, Jordyn M. Boesch, Christopher W. Frye, Wayne S. Schwark, Sabine Mann, Lisa Wolfe, Holly Brown, Erin S. Berthelsen, Joseph J. Wakshlag
Frontiers in Veterinary Science, July 2018

Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA). Methods: Single-dose pharmacokinetics was performed using two different doses of…